A Double-blind, Randomized Phase II/III Trial of Active Immunotherapy with Globo H-KLH (OPT-822) in Subjects with Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Adagloxad simolenin (Primary) ; Cyclophosphamide; OPT 821
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors OBI Pharma; Optimer Pharmaceuticals
- 02 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 Aug 2019.
- 09 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 Feb 2017.
- 09 Sep 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2016.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History